TickerTalks
Browse all tickers →
TickerTalks›$VERU
VEVERU

Veru Inc.

$VERU·$45M·Biotechnology·Healthcare
$2.38+1.3%YTD+10.2%1Y-61.2%
Mentions · last 7 days
2026-07-13: 3 posts2026-07-14: 2 posts2026-07-15: 1 posts2026-07-16: 10 posts2026-07-17: 0 posts2026-07-18: 0 posts2026-07-19: 0 posts160%
Price updated 2d ago·X counts updated 4h ago
VEVERU
$VERUVeru Inc.
$2.38+1.28%16 posts0%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Today's AI verdict on what's driving $VERU, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Hinges on a big eventWinding up for a moveAI verdict · as of 2026-07-18

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

Veru presenting at Obesity Summit — Phase 2b PLATEAU progress reported at Q2 print, tape below 200-day.

Veru is the specialty pre-commercial biotech whose thesis rests on the specific enobosarm Phase 2b PLATEAU obesity-drug-development program plus continued specific commercial-execution traction. No X sentiment sample exists for this bundle.

  • The specific fresh clinical catalyst is decisive — Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day, and Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress; those are specific real conference-and-clinical-progress datapoints supporting the enobosarm-obesity thesis.
  • The specific dated financial cadence is real — Veru Inc. (VERU) Q2 2026 Earnings Call Prepared Remarks Transcript captures the specific management-communication cadence supporting the story.
  • The specific tape signal is real — Veru (NASDAQ:VERU) Share Price Crosses Below 200 Day Moving Average — Here's Why captures the specific technical-break datapoint requiring reading against the coiling-clinical-catalyst thesis.
  • The mechanics reflect a specific pre-commercial small-cap biotech profile — gross margin at 0 (no meaningful revenue), ROIC of -73%, free-cash-flow yield about -47.8% (deeply negative), and reported debt-to-equity of only 0.08 (essentially unlevered); the low-leverage plus essentially-unlevered balance sheet defends the case.
  • The tape has been mixed — up about 10.2% year-to-date but down 61.2% over twelve months.

This coils until the next PLATEAU readout confirms continued enobosarm efficacy in obesity plus a specific commercial-partnership announcement lands — either would restart discussion; a specific safety signal or a fresh dilution filing resolves the coil lower against continued -47.8% FCF yield.

What to watch: Next PLATEAU readout for continued enobosarm efficacy in obesity plus a specific commercial-partnership. A safety signal or fresh dilution filing resolves the coil lower against -47.8% FCF yield.

no x sentimentphase 2b plateau progressobesity summit 2026below 200 day ma

Read the AI verdict + X sentiment for $VERU

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Oncology biotech developing prostate cancer treatments alongside its commercial FC2 female condom product.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $VERU.

Biotechnology · Healthcare

No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.

What this means for $VERU

Partial — Oncology biotech developing prostate cancer treatments alongside its commercial FC2 female condom product; partial earnings exposure to biotechnology demand dynamics through its product portfolio.

Top industry ETF

$IBBiShares Biotechnology ETF
+11.9%YTD
+44.0%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-5.2How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-73.1%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-47.8%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-53.4%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.1Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 13, 2026$-0.13$-0.31+58.1%
Q4 2025Feb 11, 2026$-0.26$-0.47+44.7%
Q3 2025Dec 17, 2025$-0.60$-0.36-64.4%
Q2 2025Aug 12, 2025$-0.50$-0.55+9.1%
Next earningsTue, Aug 11·consensus EPS $-0.34

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$0———$-0.13$-8.9M
Q1 FY26$0———$-0.26$-6.2M
Q4 FY25$0-100.0%——$0.09$-5.5M
Q3 FY25$0-100.0%——$-0.50$-5.5M

Forward consensus

5-year forecast · up to 3 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$2.7M$2.0M – $3.7M-$1.01-$1.53 – -$0.633
FY27$4.0M$2.8M – $5.6M-$0.98-$1.49 – -$0.622
FY28$50.0M$35.6M – $69.6M-$0.66-$0.85 – -$0.471
FY29$125.0M$88.9M – $174.1M-$0.76-$1.15 – -$0.481
FY30$0$0 – $0-$0.72-$1.09 – -$0.450

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.0×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.6%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-10.8%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-10.7%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 14.0M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.6% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β-1.185-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

No open-market buys or sells in the last 180 days.

+ 8 other (8 awards) in window

See when $VERU insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KMaterial agreementJul 28-K — Item 1.01: Material agreement
AI summary

Veru Inc. (VERU) entered into an at-the-market (ATM) Sales Agreement with Oppenheimer & Co. Inc. and Canaccord Genuity LLC on July 2, 2026, enabling Veru to sell up to $21,800,000 of common stock at prevailing market prices over time, with agents earning a 3.0% commission. The offering is registered under Veru's existing Form S-3 shelf (effective April 15, 2026), and Veru is not obligated to sell any shares. This is a dilutive but flexible funding mechanism, providing a capital runway without the price impact of a fixed-price deal.

424B5Prospectus supplement (offering)Jul 2424B5
AI summary

Veru Inc. (VERU) filed a 424B5 prospectus supplement on July 2, 2026, registering up to $21,800,000 of common stock for sale via at-the-market offering through Oppenheimer & Co. Inc. and Canaccord Genuity LLC as agents, each earning a 3.0% commission on gross proceeds. At the July 1, 2026 closing price of $3.16 per share, the program could add up to approximately 6.9 million shares to the float. Sales will occur under Rule 415(a)(4) as market conditions allow, at Veru's discretion. This prospectus supplement activates near-term dilution risk for existing shareholders.

S-3Shelf registrationApr 7S-3
S-3Shelf registrationApr 7S-3
8-KOfficer or director changeMar 138-K — Item 5.02: Officer or director change · Item 5.07: Shareholder vote
+ 15 other (2 10-Qs · 2 earnings 8-Ks · 2 EFFECTs · 2 CORRESPs) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Dayglobenewswire.com·13d agoVeru Inc. (VERU) Q2 2026 Earnings Call Prepared Remarks Transcriptseekingalpha.com·68d agoVeru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progressglobenewswire.com·68d agoVeru to Report Fiscal 2026 Second Quarter Financial Results on May 13thglobenewswire.com·75d agoVeru (NASDAQ:VERU) Share Price Crosses Below 200 Day Moving Average – Here’s Whydefenseworld.net·87d ago

In themes

Explore the broader themes this ticker is being talked about under.

Trending on X

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$SEER$QTTB$AGEN$MRNA$ATAI$ALLO$AURA$IOVA
Voices on X · last 7 days

No standout posts about $VERU on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport